Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Up 29.1% in December

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 11,000,000 shares, an increase of 29.1% from the November 30th total of 8,520,000 shares. Based on an average daily trading volume, of 690,900 shares, the short-interest ratio is currently 15.9 days. Currently, 16.3% of the shares of the stock are sold short.

Organogenesis Trading Down 2.7 %

Shares of ORGO traded down $0.09 during midday trading on Friday, reaching $3.19. The company had a trading volume of 350,648 shares, compared to its average volume of 836,492. The firm has a 50 day simple moving average of $3.46 and a 200-day simple moving average of $3.04. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The stock has a market cap of $401.07 million, a PE ratio of -53.17 and a beta of 1.73. Organogenesis has a 1-year low of $2.16 and a 1-year high of $4.70.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.11. The firm had revenue of $115.18 million during the quarter, compared to analysts' expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period last year, the business earned $0.02 earnings per share. Research analysts forecast that Organogenesis will post -0.07 EPS for the current fiscal year.

Insider Transactions at Organogenesis

In related news, CEO Gary S. Gillheeney sold 55,615 shares of Organogenesis stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total transaction of $186,866.40. Following the transaction, the chief executive officer now owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This trade represents a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 278,116 shares of company stock valued at $991,190. Corporate insiders own 36.90% of the company's stock.

Institutional Trading of Organogenesis

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its position in shares of Organogenesis by 9.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 393,798 shares of the company's stock worth $1,103,000 after purchasing an additional 33,990 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company's stock worth $44,000 after buying an additional 15,369 shares during the period. Acadian Asset Management LLC increased its position in shares of Organogenesis by 2.4% during the second quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company's stock valued at $8,605,000 after acquiring an additional 72,696 shares during the last quarter. Wealth Dimensions Group Ltd. raised its stake in shares of Organogenesis by 435.9% in the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company's stock valued at $1,142,000 after acquiring an additional 331,840 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Organogenesis by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company's stock worth $755,000 after acquiring an additional 9,054 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.